Skip to content
2000
Volume 15, Issue 6
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

The discovery of driver oncogene alterations in non-small cell lung cancer (NSCLC), such as EGFR, EML4-ALK, MET and RAS, as well as the identification of their specific targeted inhibitors have led to new opportunities for treatment of this tumor. Drug resistance, intrinsic or acquired, represents the major cause of failure of novel biological agents. MicroRNAs (miRNAs) are a family of small non-coding RNAs that can silence their cognate target genes by specifically binding mRNAs or inhibiting their translation. The recent evidences that several micro-RNAs can modulate the oncogenic driver pathways in NSCLC and that they are involved in drug resistance of their targeted inhibitors, have paved the way for new therapeutic strategies. This minireview aims 1) to explore the potential mechanisms by which key miRNAs may up-regulate or down-regulate specific oncogenic driver pathways; 2) highlight the role of microRNAs in the mechanisms of resistance to targeted therapies; 3) discuss the therapeutic potential by using short-interfering RNAs or artificial miRNAs as anti-cancer therapies.

Loading

Article metrics loading...

/content/journals/acamc/10.2174/1871520615666150121122054
2015-07-01
2025-07-12
Loading full text...

Full text loading...

/content/journals/acamc/10.2174/1871520615666150121122054
Loading

  • Article Type:
    Research Article
Keyword(s): EGFR; EML4-ALK; Micro-RNA; NSCLC; targeted therapy
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test